IracetTM (Levetiracetam) The exact mechanism of action is unknown but does not involve inhibitory and excitatory
neurotransmission. Stereo-selective binding of Levetiracetam was confined to synaptic plasma membranes in the
central nervous system with no binding occurring in peripheral tissue.
IracetTM (Levetiracetam) is indicated as an adjunctive therapy for:
.Partial Onset Seizures
.Myoclonic Seizures In Patients with Juvenile Myoclonic Epilepsy
.Primary Generalized Tonic-Clonic Seizures
IracetTM (Levetiracetam) injection is an alternative for adult patients (16 years and older) when oral administration is
temporarily not feasible.
Dosage & Administration
IracetTM (Levetiracetam) can be initiated with either intravenous or oral administration.
For tablet and oralsolution
Treatment should be initiated with a daily dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily).
Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended
daily dose of 3000 mg.
Warnings & Precaution
Severe allergic reactions, abnormal thoughts; dark urine; decreased coordination; extreme dizziness, drowsiness,
tiredness, or weakness; fever, chills, or persistent sore throat; hallucinations; memory loss; mouth sores; muscle or
neck pain; new or worsening mental problem; mood or behavior changes; new or worsening seizures; pain, itching or
redness at the injection site;suicidal thoughts or attempts; unusual bruising or bleeding; vision changes; yellowing of
the skin or eyes.
Dizziness, drowsiness, irritability, sore throat, tiredness, weakness are some common adverse effects. In rare cases
severe allergic reaction may happen.
No potential drug interaction has been reported
Use In Pregnancy And Lactation
Pregnancy: Pregnancy category C.
Lactation: No data on the use of Levetiracetam in breast-feeding women are available. Data from animals indicate
that Levetiracetam is secreted into milk.Therefore Levetiracetam is contraindicated during breast-feeding